Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethynodiol diacetate is a synthetic progestin used primarily as an active ingredient in oral contraceptives. It acts as a prodrug, rapidly converted in the body to norethisterone, which exerts its contraceptive effects by binding to progesterone and estrogen receptors in target tissues such as the female reproductive tract, mammary gland, hypothalamus, and pituitary. This action suppresses ovulation by inhibiting gonadotropin-releasing hormone (GnRH) release from the hypothalamus and blunting the preovulatory luteinizing hormone (LH) surge. Ethynodiol diacetate also has weak androgenic and some estrogenic activity. It was first synthesized in 1954 and introduced for medical use in 1965[2][5]. The drug's primary indication is contraception. Ethynodiol diacetate is most commonly used in combination with ethinyl estradiol for oral contraception; it is marketed under various brand names worldwide but only available in a few countries today[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethynodiol diacetate.